Alpha-glucosidase inhibitor and application thereof in hypoglycemic drugs or functional foods

A glucosidase and hypoglycemic technology, which is applied in the directions of food ingredients, applications and food ingredients containing natural extracts, can solve problems such as liver damage and gastrointestinal dysfunction, and achieve good biocompatibility and good blood sugar reduction. effect of effect

Active Publication Date: 2020-05-26
XISHUANGBANNA TROPICAL BOTANICAL GARDEN CHINESE ACAD OF SCI
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, α-glucosidase inhibitors such as acarbose, which are widely used clinically, can easily cause gastrointestina

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Alpha-glucosidase inhibitor and application thereof in hypoglycemic drugs or functional foods
  • Alpha-glucosidase inhibitor and application thereof in hypoglycemic drugs or functional foods
  • Alpha-glucosidase inhibitor and application thereof in hypoglycemic drugs or functional foods

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Example 1: Evaluation of the inhibitory activity of draconatin A on α-glucosidase

[0032] Experimental principle:

[0033] α-glucosidase belongs to oligosaccharide hydrolase, and its inhibitor reduces the degradation of carbohydrates by competitively inhibiting the action of glucosidases on the chorionic epithelium of the small intestine, delaying the digestion and absorption of carbohydrates, thereby effectively reducing the risk of diabetes The peak value of blood sugar concentration after a meal can achieve the purpose of controlling blood sugar. α-glucosidase inhibitors (such as acarbose, etc.) have become a class of oral hypoglycemic drugs widely used clinically.

[0034] The activity screening of α-glucosidase inhibitors can be detected by the in vitro enzymatic reaction of the enzyme with its substrate p-nitrophenyl-β-D-galactopyranoside (PNPG, maltose analogue). After α-glucosidase is added to the substrate of the enzyme reaction, the substrate is decomposed ...

Embodiment 2

[0046] Tablet: Mix 4g of draconin A with 3g of lactose and 2.5g of starch, moisten evenly with water, sieve the wetted mixture and dry, then sieve, add 0.5g of magnesium stearate, mix well, press Tablets, compressed into 100 tablets, tablet weight: 100mg, content: 40mg / tablet.

Embodiment 3

[0048] Capsules: Mix 4g of draconin A with 2.5g of lactose and 0.5g of magnesium stearate, sieve, mix evenly, put the obtained mixture into hard gelatin capsules, capsule weight: 70mg, content: 40mg / grain.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a new application of dracorhodin A, including an application of dracorhodin A in preparation of hypoglycemic drugs, health-care products or functional foods, and further including an application of dracorhodin A in preparation of an alpha-glucosidase activity inhibitor. The application creatively finds that dracorhodin A can inhibit the activity of alpha-glucosidase, and theinhibitory activity of dracorhodin A is far higher than that of acarbose serving as a clinical drug. The invention also provides a hypoglycemic composition, which comprises dracorhodin A and pharmaceutic adjuvants or health-care product adjuvants, and is used as a pharmaceutical preparation or a health-care product preparation.

Description

technical field [0001] The present invention relates to the field of application of medicine or health care products, in particular to an α-glucosidase inhibitor and its application in hypoglycemic drugs or functional foods, especially to the use of draconatin A in the preparation of α-glucosidase inhibitors Drugs and hypoglycemic drugs or functional food applications. Background technique [0002] Diabetes is a comprehensive metabolic disease characterized by hyperglycemia, mainly divided into type 1 diabetes and type 2 diabetes. There are currently about 424 million diabetic patients in the world, and with the improvement of modern living standards, aging population and increasing incidence of obesity, the incidence of diabetes will further increase rapidly. Sustained high blood sugar and long-term metabolic disorders in diabetes can lead to damage, dysfunction and failure of tissues and organs throughout the body, especially the cardiovascular, eye, kidney and nervous sy...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/352A61K36/896A61P3/10A23L33/105
CPCA23V2002/00A61K31/352A61K36/896A23L33/105A61P3/10A23V2250/21A23V2200/328
Inventor 张玉梅杨周颖
Owner XISHUANGBANNA TROPICAL BOTANICAL GARDEN CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products